Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00253331 · ClinicalTrials.gov registry record · Phase 2
Lab Study of MQX-503 in Treatment of Raynaud's
A Phase 2 study of Raynaud Disease and Raynaud Disease Secondary to Scleroderma, sponsored by MediQuest Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT00253331 is a Phase 2 study of Raynaud Disease and Raynaud Disease Secondary to Scleroderma that has completed, run by MediQuest Therapeutics. The registered enrollment target is 36 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00253331, a Phase 2 study of Raynaud Disease and Raynaud Disease Secondary to Scleroderma, has completed, sponsored by MediQuest Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine, in comparison to a placebo control, the response to two dosage strengths of a topical gel formulation of nitroglycerin, MQX-303, in the determination of finger blood flow and skin temperature in the fingers of patients with moderate to severe Raynaud's phenomenon, follwoing exposure to cold temperatures. Blood flow is determined by scanning laser Doppler equipment and skin temperature is measured using attached thermistor probes. Following baseline measurements, the study gel is applied, the hand is placed in a cold chamber, and then blood flow and skin temperature are monitored for the next two hours. Each patient will receive multiple doses on different days so that each can serve as his/her own control in interpreting the response.
Conditions Studied
Interventions
- DRUG topical organogel with nitroglycerin
Study Locations (2)
Maryland
- Johns Hopkins Bayview Medical Center - Baltimore
Washington
- University of Washington Medical College - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-11 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00253331
The ClinicalTrials.gov registry entry for NCT00253331 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediQuest Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Raynaud Disease appearing as the primary indexed condition, and to 1 intervention - of which topical organogel with nitroglycerin is the first listed.
NCT00253331 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Washington.
Frequently Asked Questions
What is clinical trial NCT00253331 about?
NCT00253331 is a clinical study titled "Lab Study of MQX-503 in Treatment of Raynaud's". The purpose of this study is to determine, in comparison to a placebo control, the response to two dosage strengths of a topical gel formulation of nitroglycerin, MQX-303, in the determination of finger blood flow and skin temperature in the fingers of patients with moderate to severe Raynaud's phen...
What is the current status of trial NCT00253331?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2004-11. Estimated completion is 2005-09.
What conditions does trial NCT00253331 study?
This clinical trial studies the following conditions: Raynaud Disease, Raynaud Disease Secondary to Scleroderma, Raynaud Secondary to Other Autoimmune Disease.
What interventions are being tested in trial NCT00253331?
The interventions under investigation include: topical organogel with nitroglycerin (DRUG).
Who is sponsoring clinical trial NCT00253331?
This trial is sponsored by MediQuest Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00253331 being conducted?
This trial has 2 study locations across Maryland, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.